Literature DB >> 15592335

Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients.

Tuire Tirkkonen1, Kari Laine.   

Abstract

OBJECTIVE: Our objective was to investigate the frequency of potential drug-drug interactions between the prodrugs losartan, codeine, and tramadol and drugs known to inhibit their activation in hospitalized patients.
METHODS: The frequency of coadministration between losartan and well-established cytochrome P450 (CYP) 2C9 inhibitors, as well as codeine and tramadol and CYP2D6 inhibitors, was studied by use of data from a university hospital medication database. The study population comprised all patients treated in internal medicine, pulmonary medicine, oncology, and neurology wards (105,533 treatment periods and 65,526 patients) between July 1, 1996, and June 30, 2002 (6 years).
RESULTS: Every fifth patient receiving losartan, codeine, or tramadol was concomitantly taking another drug that has the potential to inhibit the activation of these drugs. During the 6-year time period, 1999 patients were exposed to a potential interaction. Interactions occurred more commonly in internal medicine wards (odds ratio, 2.3; 95% confidence interval, 2.1-2.5) and in women (odds ratio, 1.5; 95% confidence interval, 1.4-1.7).
CONCLUSIONS: Coadministration of drugs that potentially result in inhibition of prodrug activation present a common and unrecognized source of irrational prescribing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592335     DOI: 10.1016/j.clpt.2004.08.017

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  SFINX-a drug-drug interaction database designed for clinical decision support systems.

Authors:  Ylva Böttiger; Kari Laine; Marine L Andersson; Tuomas Korhonen; Björn Molin; Marie-Louise Ovesjö; Tuire Tirkkonen; Anders Rane; Lars L Gustafsson; Birgit Eiermann
Journal:  Eur J Clin Pharmacol       Date:  2009-02-11       Impact factor: 2.953

2.  Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.

Authors:  Tuukka Saarikoski; Teijo I Saari; Nora M Hagelberg; Janne T Backman; Pertti J Neuvonen; Mika Scheinin; Klaus T Olkkola; Kari Laine
Journal:  Eur J Clin Pharmacol       Date:  2015-01-06       Impact factor: 2.953

Review 3.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

4.  A service improvement project to review prescribing information provided by general practitioners for new referrals to a UK National Health Service hospital pain clinic: potential implications of CYP2D6 enzyme inhibition.

Authors:  Helen Radford; Pauline Fitzgerald; Stephen Martin; Mark I Johnson
Journal:  Br J Pain       Date:  2016-07-05

5.  Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions.

Authors:  Buster Mannheimer; Björn Wettermark; Michael Lundberg; Hans Pettersson; Christer von Bahr; Erik Eliasson
Journal:  Br J Clin Pharmacol       Date:  2010-04       Impact factor: 4.335

Review 6.  Pharmacogenomics: the genetics of variable drug responses.

Authors:  Dan M Roden; Russell A Wilke; Heyo K Kroemer; C Michael Stein
Journal:  Circulation       Date:  2011-04-19       Impact factor: 29.690

7.  Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction.

Authors:  Nora M Hagelberg; Tuukka Saarikoski; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Miia Turpeinen; Mika Scheinin; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2012-10-26       Impact factor: 2.953

8.  Rifampicin markedly decreases the exposure to oral and intravenous tramadol.

Authors:  Tuukka Saarikoski; Teijo I Saari; Nora M Hagelberg; Mikko Neuvonen; Pertti J Neuvonen; Mika Scheinin; Klaus T Olkkola; Kari Laine
Journal:  Eur J Clin Pharmacol       Date:  2012-12-15       Impact factor: 2.953

Review 9.  Drug Interaction and Serotonin Toxicity with Opioid Use: Another Reason to Avoid Opioids in Headache and Migraine Treatment.

Authors:  Hossein Ansari; Leila Kouti
Journal:  Curr Pain Headache Rep       Date:  2016-08

10.  The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis.

Authors:  David C Brousseau; D Gail McCarver; Amy L Drendel; Karthika Divakaran; Julie A Panepinto
Journal:  J Pediatr       Date:  2007-06       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.